Literature DB >> 14614180

The rapid development of fluoroquinolone resistance in M. tuberculosis.

Amy Sarah Ginsburg, Samuel C Woolwine, Nancy Hooper, William H Benjamin, William R Bishai, Susan E Dorman, Timothy R Sterling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14614180     DOI： 10.1056/NEJM200311133492023

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  20 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.

Authors:  Abdullah Alsultan; Guohua An; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 3.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 4.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.

Authors:  Anandi Martin; Juan Carlos Palomino; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 6.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

7.  Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.

Authors:  J-Y Wang; P-R Hsueh; I-S Jan; L-N Lee; Y-S Liaw; P-C Yang; K-T Luh
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

8.  Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

9.  Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Authors:  Shashikant Srivastava; Sandirai Musuka; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

10.  Tuberculosis a re-emerging disease.

Authors:  Saverio De Lorenzo; Simon Tiberi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.